Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-06-12
2007-06-12
Rawlings, Stephen (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S144100, C424S154100, C424S277100, C530S350000, C530S388750
Reexamination Certificate
active
09454851
ABSTRACT:
T cell activation in response to antigen is increased by the administration of binding agents that block CTLA-4 signaling. When CTLA-4 signaling is thus blocked, the T cell response to antigen is released from inhibition. Such an enhanced response is useful for the treatment of tumors, chronic viral infections, and as an adjuvant during immunization.
REFERENCES:
patent: 4108983 (1978-08-01), Wallack
patent: 4243663 (1981-01-01), Azuma et al.
patent: 5434131 (1995-07-01), Linsley et al.
patent: 5556763 (1996-09-01), Ochoa et al.
patent: 5637483 (1997-06-01), Dranoff et al.
patent: 5925362 (1999-07-01), Spitler et al.
patent: 5968510 (1999-10-01), Linsley et al.
patent: 5977318 (1999-11-01), Linsley et al.
patent: 6719972 (2004-04-01), Gribben et al.
patent: 0 613 944 (1994-09-01), None
patent: 0 682 039 (1995-11-01), None
patent: 93/00431 (1993-01-01), None
patent: 95/01994 (1995-01-01), None
patent: 95/03408 (1995-02-01), None
patent: 95/05464 (1995-02-01), None
patent: 95/23859 (1995-09-01), None
patent: 95/24217 (1995-09-01), None
patent: 95/33770 (1995-12-01), None
patent: 95/34320 (1995-12-01), None
patent: 96/14865 (1996-05-01), None
Bodey, B, et al, Failure of cancer vaccines: the significant limitations of this approach to immunotherapy, Anticancer Research, vol. 20, pp. 2665-2676.
Timmerman, JM, et al, 1999, Dendritic cell vaccines for cancer immunotherapy, Annual Review of Medicine, vol. 50, pp. 507-529.
Arceci, RJ. 1998, The potential for antitumor vaccination in acute myelogenous leukemia, Journal of Molecular Medicine, vol. 76, pp. 80-93.
Pardoll, DM, 1993, Cancer vaccines, Immunology Today, vol. 14, pp. 310-316.
Lee, K-H, et al, 1999, Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression, Journal of Immunology, vol. 163, pp. 6292-6300.
Zaks, TZ, et al, 1998, Immunization with a peptide epitope (p369-377) from HER-2
eu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2
eu+ tumors, Cancer Research, vol. 58, pp. 4902-4908.
Zhu, J, et al, 2001, Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade enhances incidence and severity of experimental autoimmune neurtitis in resistant mice, Journal of Neuroimmunology 115: 111-117.
Yang, Y-F, et al, 1997, Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages, Cancer Research, vol. 57, pp. 4036-4041.
Anderson, DE, et al, 2000, Paradoxical inhibition of T-cell function in response to CTLA-4 blockade; heterogeneity within the human T-cell population, Nature Medicine, vol. 6, pp. 211-214.
Leach, DR, et al, 1996, Enhancement of antitumor immunity by CTLA-4 blockade, Science, vol. 271, pp. 1734-1736.
Chambers, CA, et al, 1997, Thymocyte development is normal in CTLA-4-deficient mice, Proceedings of the National Academy of Sciences USA, vol. 94, pp. 9296-9301.
Gribben, G, et al, 1994, Alloantigen and concomitant CTLA4 signaling induces clonal deletion of alloreactive T cells, Blood, vol. 84, pp. 397a (meeting abstract).
Lewis, GD, et al, 1996, Growth regulation of human breast and ovarian tumor cells by heregulin: evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness, Cancer Research, vol. 56, 1457-1465.
Gao, P, et al, Tumor vaccination that enhances antitumor T-cell responses does not inhibit the growth of established tumors in combination with interleukin-12 treatment, Journal of Immunotherapy, vol. 23, pp. 643-653.
Sullivan, TJ, et al, 1998, Induction of CNS inflammatory disease as a consequence of CTLA-4/B7 blockade, FASEB Journal, vol. 12, pp. A1092 (meeting abstract).
Sotomayor, EM, et al, 1999, In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance, Proceedings of the National Academy of Science USA, vol. 96, pp. 11476-11481.
Christadoss, P, et al, 2000, Animal models of myasthenia gravis, Clinical Immunology, vol. 94, pp. 75-87.
Triozzi, PL, et al, 1994, Clinical and immunologic effects of a synthetic beta-human chorionic gonadotropin vaccine, International Journal of Oncology, vol. 5, pp. 1447-1453.
Heslop, HE, 1994, Cytokine gene transfer in the therapy of malignancy, Baillieres Clinical Haematology, vol. 7, pp. 135-151 (abstract only), MEDLINE 8038497.
Wallack, MK, et al, 1992, Active specific immunotherapy with vaccinia melanoma oncolysate, Mt. Sinai Journal of Medicine, vol. 59, pp. 227-233 (abstract only), MEDLINE 1318507.
Anderson DE, et al. Nature Medicine 2000 Feb; 6 (2): 211-14.
Devlin et al., “Random Peptide Libraries: A Source of Specific Protein Binding Molecules,” Science, 249:404-406 (1990).
Oldenburg et al. “Peptide ligands for a sugar-binding protein isolated from a random peptide library,” Proc. Natl. Acad. Sci. USA. 89: 5393-5397 (1992).
Sparks et al., “Identification and Characterization of Src SH3 Ligands from Phage-displayed Random Peptide Libraries,” Journal of Biological Chemistry, 269(39):23853-23856 (1994).
Goodson et al., “High-affininity urokinase receptor antagonists identified with bacteriophage peptide display,” Proc. Natl. Acad. Sci. USA, 91:7129-7133 (1994).
Yanofsky et al., “High-affinity type I interleukin 1 Receptor antagonists discovered by screening recombinant peptide libraries,” Proc. Natl. Acad. Sci. USA, 93:7381-7386 (1996).
Chaudhary et al., “Caloxin: a novel plasma membrane CA2+pump inhibitor,” Am. J. Physiol. Cell Physiol., 280: C1027-C1030 (2001).
Xu et al., “A Novel PCNA— Binding Motif Identified by the Panning of a Random Peptide Display Library,” Biochemistry, 40:4512-4520 (2001).
Wu et al., “CTLA-4-B7 Interaction is Sufficient to Costimulate T Cell Clonal Expansion,”J. Exp. Med.185(7):1327-1335 (1997).
Linsley, P,S., “Distinct Roles for CD28 and Cytotoxic Lymphocyte-Associated Molecule-4 Receptors During T Cell Activation,”J. Exp. Med., 182:289-292 (1995).
June et al., “B7 and CD28 Receptor Families,”Immunology Today, 15(7):321-331 (1994).
Linsley et al., “Coexpression and Functional Cooperation of CTLA-4 anc CD28 on Activated T Lymphocytes,”J. Exp. Med.176:1595-1604 (1992).
Chen et al., “Costimulation of Antitumor Immunity by the B7 Counterreceptor for the T Lymphocyte Molecules CD28 and CTLA-4,”Cell71:1093-1102 (1992).
Freeman et al., “Uncovering of Functional Alterenative CTLA-4 Counter-Receptor in B7-Deficient Mice,”Science262:907-909 (1993).
Lenschow et al., “Expression and Functional Significance of an Additional Ligand for CTLA-4,”Proc. Natl. Acad. Sci. USA90:11054-11058 (1993).
Jenkins, M.K., “The Ups and Downs of T Cell Costimulation,”Immunity1:443-446 (1994).
Walunas et al., “CTLA-4 Can Function as a Negative Regulator of T Cell Activation,”Immunity1:405-413 (1994).
Schwartz, R.H., “Costimulation of T Lymphocytes: The Role of CD28, CTLA-4, and B7/BB1 in Interleukin-2 Production and Immunotherapy,”Cell71:1065-1068 (1992).
Linsley et al., “CTLA-4 Is a Second Receptor for the B Cell Activation Antigen B7,”J. Exp. Med.174:561-569 (1991).
Linsley et al., “Immunosuppression in Vivo by a Soluble Form of the CTLA-4 T Cell Activation Molecule,”Science257:792-795 (1995).
Lenschow et al., “Long-Term Survival of Xenogeneic Pancreatic Islet Grafts Induced by CTLA4lg,”Science257:789-792 (1992).
Brunet et al., “A New Member of the Immunoglobulin Superfamily-CTLA-4,”Nature328:267-270 (1987).
Harding et al., “CD28-Mediated Signaling Co-Stimulates Murine T Cells and Prevents Induction of Anergy in T-Cell Clones,”Nature356:607-609 (1992).
Townsend, S.E. and J.P. Allison, “Tumor Rejection After Direct Costimulation of CD8+ T Cells by B7-Transfected Melanoma Ce
Allison James Patrick
Krummel Matthew E.
Leach Dana R.
Dorsey & Whitney LLP
Lorenz Todd A.
Rawlings Stephen
The Regents of the University of California, Office of Technolog
LandOfFree
Blockade of T lymphocyte down-regulation associated with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Blockade of T lymphocyte down-regulation associated with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Blockade of T lymphocyte down-regulation associated with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3876503